T h e ne w e ngl a nd jou r na l o f m e dicine n engl j med 370;15 nejm.org april 10, 2014 1384 M any patients with heart failure have a normal or near-normal left ventricular ejection fraction. [1] [2] [3] [4] Such patients share common signs and symptoms, as well as an impaired quality of life and a poor prognosis, with patients who have heart failure and a reduced ejection fraction. [5] [6] [7] [8] However, the benefit of most medical therapies for heart failure is limited to those with a reduced ejection fraction, generally 40% or less. 1, 2, 9 The lack of favorable evidence from clinical-outcome trials involving patients with heart failure and a preserved left ventricular ejection fraction is reflected in current guidelines, which offer no specific recommendations for the management of heart failure in such patients except for attention to coexisting conditions. [10] [11] [12] Among patients with heart failure and a reduced ejection fraction and those with myocardial infarction complicated by heart failure and left ventricular dysfunction, mineralocorticoidreceptor antagonists have been shown to be effective in reducing overall mortality and hospitalizations for heart failure. [13] [14] [15] In small mechanistic studies involving patients with heart failure and preserved left ventricular function, mineralocorticoid-receptor antagonists improved measures of diastolic function. 16, 17 However, their effect on clinical outcomes in such patients has not been rigorously tested. We therefore initiated the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial to determine whether treatment with spironolactone would improve clinical outcomes in patients with symptomatic heart failure and a relatively preserved ejection fraction. 18, 19 Me thods
Study Design and Oversight
We designed a phase 3, multicenter, international, randomized, double-blind, placebo-controlled trial. The trial was sponsored by the National Heart, Lung, and Blood Institute. The executive and steering committees designed the trial and oversaw its conduct; the ethics committee at each study site approved the trial design. Data were collected and managed electronically by the New England Research Institutes Clinical Trial Coordinating Center, which also coordinated site monitoring and analyzed the trial results (with independent verification at Brigham and Women's Hospital). The first draft of the manuscript was written by the first three authors and the last author. All the authors edited and approved the manuscript and assume full responsibility for the accuracy and completeness of the data and for the fidelity of this report to the study protocol, which is available with the full text of this article at NEJM.org. Further details concerning study design and oversight are provided in the Supplementary Appendix, available at NEJM.org.
Study Patients
Patients 50 years of age or older were eligible if they provided written informed consent and had at least one sign and at least one symptom of heart failure on a prespecified list of clinically defined signs and symptoms, a left ventricular ejection fraction of 45% or more as measured at the local site by means of echocardiography or radionuclide ventriculography, controlled systolic blood pressure (defined as a target systolic blood pressure of <140 mm Hg or ≤160 mm Hg if the patient was taking three or more medications to control blood pressure), and a serum potassium level of less than 5.0 mmol per liter. In addition, eligible patients had a history of hospitalization within the previous 12 months, with management of heart failure a major component of the care provided (not adjudicated by the clinical-events adjudication committee), or an elevated natriuretic peptide level within 60 days before randomization (a brain natriuretic peptide [BNP] level ≥100 pg per milli liter or an N-terminal pro-BNP [NTproBNP] level ≥360 pg per milliliter). Trial randomization was stratified according to whether patients were enrolled on the basis of the first criterion (designated the hospitalization stratum) or the second criterion (designated the BNP stratum). The second criterion was considered only for those who did not meet the first criterion.
Exclusion criteria were severe systemic illness with a life expectancy of less than 3 years, severe renal dysfunction (an estimated glomerular filtration rate [GFR] of <30 ml per minute per 1.73 m 2 of body-surface area or a serum creatinine level that was ≥2.5 mg per deciliter [221 μmol per liter]), and specific coexisting conditions, medications, or acute events. 19 A full list of inclusion and exclusion criteria is provided in the Supplementary Appendix.
Randomization and Study Drugs
Eligible participants were randomly assigned to receive either spironolactone or placebo in a 1:1 ratio with the use of permuted blocks. As noted above, randomization was stratified according to whether the patient met the criterion for previous hospitalization or BNP elevation. Study drugs were purchased as 15-mg tablets of spironolactone or matching placebo (United Research Laboratories and Mutual Pharmaceutical). Study drugs were initially administered at a dose of 15 mg once daily, which was increased to a maximum of 45 mg daily during the first 4 months after randomization. Subsequent dose adjustments were made as required. Measurement of potassium and creatinine levels was required within 1 week after a change in the study-drug dose and at each scheduled study visit (Fig. S1 in the Supplementary Appendix). Study patients continued to receive other treatments for heart failure and co existing illnesses throughout the trial. Further details concerning dose adjustments and follow-up assessments are provided in the Supplementary Appendix.
Outcomes
The primary outcome was a composite of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for the management of heart failure. All occurrences of the individual components of the primary outcome, as well as myocardial infarctions and strokes, were adjudicated by a clinical end-point committee at Brigham and Women's Hospital according to prespecified criteria; members of the committee were unaware of the study-drug assignments. 18 Other outcomes included death from any cause, hospitalization for any cause, hyperkalemia (potassium level, ≥5.5 mmol per liter), hypokalemia (potassium level, <3.5 mmol per liter), an elevated serum creatinine level (≥2 times the baseline value and above the upper limit of the normal range), and a serum creatinine level of 3.0 mg per deciliter (265 μmol per liter) or higher. A detailed summary of the criteria defining the individual trial-outcome measures reported here is provided in the Supplementary Appendix.
Statistical Analysis
The trial was designed to have 80% power to detect a 20% relative reduction from a 3-year primary outcome rate of 17.4%, with an overall type I error of 0.05 (two-sided test). After accounting for interim monitoring (see the Methods section in the Supplementary Appendix), we calculated that data on 551 participants with primary outcomes confirmed by the clinical end-point committee would be needed to achieve 80% power, and data on 630 participants with primary outcomes would be needed to achieve 85% power. The target enrollment was 3515 patients. 18 All randomly assigned participants were included in all analyses according to the intentionto-treat principle. For prespecified comparisons of multiple hospitalizations, the planned Poisson regression model was replaced with a negative binomial model to allow for correlated events. All other analyses were prespecified unless stated otherwise. Participants were followed for clinical and laboratory outcomes through their last semiannual visit, between January 1, 2013, and June 30, 2013, or until the last contact. For those who withdrew or were lost to follow-up, attempts were made to obtain vital status as of the last potential study visit.
The prespecified primary analysis was a timeto-event analysis with the use of the unadjusted log-rank test. Cox proportional-hazards models were used to obtain unadjusted and covariateadjusted hazard ratios. Data on participants who did not have a primary-outcome event were censored at the date of last available follow-up information for clinical events. The same approach was used for other time-to-event outcomes. For death from any cause, data were censored on the last date that the participant was known to be alive, which may have been later than the last clinical follow-up. Incidence rates per 100 personyears were also calculated.
Comparisons of recurrent hospitalizations for heart failure and hospitalizations for any cause were performed with the use of negative binomial regression. Longitudinal linear regression methods, without adjustment, were used for laboratory and blood-pressure measurements. A total of 22 prespecified subgroup analyses were conducted for the primary outcome. To assess the homogeneity of study-drug effects across subgroups, we used a Cox proportional-hazards model, including study group, the subgroup variable, and their interaction. 20 No adjustments were made for multiple comparisons. signed to receive spirono lactone (1722 participants) or placebo (1723). A total of 2464 participants (71.5%) were enrolled in the hospitalization stratum, and 981 (28.5%) were enrolled in the BNP stratum (Fig. S2 in the Supplementary Appendix). The study groups were balanced with respect to baseline characteristics (Table 1,  and Table S1 in the Sup plementary Appendix). The mean follow-up interval was 3.3 years in each study group. A total of 311 participants -160 in the spironolactone group (9.3%) and 151 in the placebo group (8.8%) -discon tinued study participation before the last expected study visit for reasons other than death (Fig. S2 in the Supplementary Appendix). Vital status as of the last expected study visit was unknown for 67 participants in the spironolactone group (3.9%) and 65 participants in the placebo group (3.8%).
Study Drug Administration
The distribution of daily study-drug doses at 8 months after randomization is shown according to study group in Table S2 in the Supplementary Appendix. The mean dose at 8 months was 25.0 mg per day in the spironolactone group and 27.7 mg per day in the placebo group. There were 590 participants in the spironolactone group (34.3%) and 541 in the placebo group (31.4%) who permanently discontinued the study drug while continuing to be followed for study outcomes. Tables S3A and S3B in the Supplementary Appendix show the timing of and reasons for early discontinuation of the study drug.
Primary-Outcome and Component Events
A total of 671 participants had at least one confirmed primary-outcome event: 320 in the spironolactone group (18.6%) and 351 in the placebo group (20.4%). These numbers correspond to incidence rates of 5.9 events per 100 person-years and 6.6 events per 100 person-years, respectively (P = 0.14 by the log-rank test). The unadjusted hazard ratio was 0.89 (95% confidence interval [CI], 0.77 to 1.04) ( Table 2 and Fig. 1 ). The inci- * There were no significant differences between the two groups except as indicated. GFR denotes glomerular filtration rate, and NYHA New York Heart Association. dence rates and the adjusted models are shown in Table S4 in the Supplementary Appendix. Death from cardiovascular causes occurred in 160 patients in the spironolactone group (9.3%) and 176 patients in the placebo group (10.2%), with a hazard ratio of 0.90 (95% CI, 0.73 to 1.12; P = 0.35 by the log-rank test) ( Fig. 2A) . Aborted cardiac arrest occurred in 3 patients in the spironolactone group (0.2%) and 5 patients in the placebo group (0.3%) (P = 0.48 by the log-rank test). Hospitalization for heart failure occurred in 206 patients in the spironolactone group (12.0%) and 245 patients in the placebo group (14.2%), with a hazard ratio of 0.83 (95% CI, 0.69 to 0.99; P = 0.04 by the log-rank test) (Fig. 2B) . Approximately two thirds of first primary-outcome events were hospitalizations for heart failure. In an analysis of total hospitalizations (including repeat hospitalizations) for heart failure over the entire study period, the frequency was lower in the spironolactone group than in the placebo group (394 vs. 475 hospitalizations; 6.8 vs. 8.3 per 100 person-years; P = 0.03).
The results of analyses of the primary outcome in 22 prespecified subgroups are shown in Figure S3 in the Supplementary Appendix. Studydrug effects differed significantly only according to randomization stratum (P = 0.01 for interac- The primary outcome was a composite of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for the management of heart failure. The inset shows the same data on an expanded y axis.
The tion). In the hospitalization stratum, spiro no lactone had no effect on the time to the composite outcome (hazard ratio, 1.01; 95% CI, 0.84 to 1.21; P = 0.92), whereas in the BNP stratum, spironolactone showed a benefit (hazard ratio, 0.65; 95% CI, 0.49 to 0.87; P = 0.003) (see Table S5A in the Supplementary Appendix for the primary outcome and its components according to randomization stratum). As compared with patients in the hospitalization stratum, patients in the BNP stratum were older; were less likely to be current smokers; had higher baseline creatinine levels, lower potassium levels, and lower estimated GFRs; and were less likely to be enrolled at sites in Russia or Georgia (Table S5B in the Supplementary Appendix). Post hoc analysis indicated marked regional differences in event rates (Table S6 in the Supplementary Appendix). In the Americas (the United States, Canada, Brazil, and Argentina), the primary outcome occurred in 242 patients in the spironolactone group (27.3%) and 280 patients in the placebo group (31.8%). In Russia and Georgia, the primary outcome occurred in 78 patients in the spironolactone group (9.3%) and 71 patients in the placebo group (8.4%). However, the prespecified test for interaction between region and study group was not significant (P = 0.12) (Fig. S3 in the Supplementary Appendix).
Secondary Outcomes
There were no significant differences between study groups in time to death from any cause or first hospitalization for any reason (Table 2 and Fig. 3, and Fig. S4 in the Supplementary Appendix). Causes of death were generally similar between the two groups (Table S7 in the Supplementary Appendix). The frequency of hospitalization for any reason (including recurrent hospitalization) did not differ significantly according to study group (36.8 hospitalizations per 100 personyears in the spironolactone group and 36.3 per 100 person-years in the placebo group, P = 0.71). There were no significant differences in rates of myocardial infarction or stroke between the groups (Table 2) .
Adverse Events
There were 2395 serious adverse events in the spironolactone group and 2387 in the placebo group (41.6 per 100 person-years and 41.8 per 
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100 person-years, respectively). The spironolactone group had a higher rate of hyperkalemia (18.7%, vs. 9.1% in the placebo group) and a lower rate of hypokalemia (16.2% vs. 22.9%). The spironolactone group was more likely to have a doubling of the serum creatinine level to a value above the upper limit of the normal range (10.2% vs. 7.0%). However, there were no significant between-group differences in the proportion of patients with a serum creatinine level of 3.0 mg per deciliter or higher or who required dialysis. Systolic blood pressure at postbaseline visits was significantly lower in the spironolactone group. In addition, discontinuation of the study drug due to breast tenderness or gynecomastia was significantly more frequent in the spironolactone group. A more detailed description of the adverse events is provided in the Supplementary Appendix, including Table S8 .
Discussion
The TOPCAT trial was adequately powered for its composite primary outcome of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for heart failure. We found that adding spironolactone to existing therapy in patients with heart failure and a preserved ejection fraction did not significantly reduce the incidence of the primary outcome.
Neither the time to first hospitalization for any reason nor the time to death from any cause was significantly altered by random assignment to spironolactone. These two inclusive outcome measures are important for assessing overall risk versus benefit but were not anticipated to be significantly reduced by a therapy addressing only one aspect of the broad range of coexisting conditions in this patient population. The incidence rates of death from any cause and of hospitalization for heart failure in our placebo group (4.6 events per 100 person-years for each outcome) are similar to rates observed in other major trials involving patients with heart failure and a preserved ejection fraction [21] [22] [23] [24] [25] and are considerably higher than those in trials involving patients with hypertension, 26 diabetes, 27 or stable coronary artery disease. 28, 29 In the context of a neutral primary finding, all other secondary analyses should be considered as provisional. However, the individual components of any composite primary end point are always important in interpreting the overall trial result. Death from cardiovascular causes occurred in approximately 10% of patients and did not differ significantly between the study groups. Survival of a documented cardiac arrest occurred in only eight patients. Hospitalization for heart failure was the most common component of the primary outcome, and the rate of this outcome was reduced in the spironolactone group, a finding that was reinforced by the results of a prespecified analysis of cumulative hospitalizations for heart failure.
Of the 22 prespecified subgroups, only the eligibility stratum was associated with a significant treatment interaction. Spironolactone significantly reduced the rate of the primary outcome among patients enrolled on the basis of an elevated natriuretic peptide level but not among those enrolled on the basis of a previous hospitalization for heart failure. This could be a chance finding, given the multiple analyses. However, we noted multiple differences in the baseline characteristics of patients according to stratum. In the placebo group in the TOPCAT trial, there was an unexpectedly lower risk 30, 31 of the primary outcome among those who had been hospitalized previously than among those who had not (Table S5A in the Supplementary Appendix). In addition, the great majority of patients from Russia and Georgia were enrolled in the hospitalization stratum, whereas patients from the Americas were more evenly balanced between the two strata (Table S5B in the Supplementary Appendix) . These unanticipated observations led to additional, exploratory post hoc analyses. We observed a marked regional variation in event rates, with patients in the placebo group who were enrolled in Russia or Georgia having a much lower likelihood of a primary-outcome event than those enrolled in the Americas (Table S6 in the Supplementary Appendix). This discrepancy in event rates with placebo was unexpected and is unexplained. However, it may reflect regional heterogeneity of coexisting conditions and practice patterns, [32] [33] [34] [35] including differential use of hospitalization, as well as the clinical challenges in diagnosing heart failure with a preserved ejection fraction. 36 The discrepancy in event rates with placebo may have contributed to the observed treatment benefit in the Americas but not in Russia or Georgia (where low event rates would be difficult to reduce further) and the observed treatment benefit among patients enrolled in the BNP stratum but not among those enrolled in the hospitalization stratum (because most of the patients enrolled in Russia and Georgia were in the hospitalization stratum).
The achieved dose of spironolactone in the TOPCAT trial was similar to the mean dose in the Randomized Aldactone Evaluation Study, 14 and dose adjustments were limited by elevations in serum creatinine and potassium levels. Approximately one third of participants discontinued the study drug for these and other reasons, which is an additional important limitation of our trial. There was a significant increase in hyperkalemia and an increase in serum creatinine levels with spironolactone, findings that underscore the importance of monitoring if spironolactone is used in patients with heart failure and a preserved ejection fraction.
In conclusion, we compared spironolactone with placebo for the treatment of heart failure with a preserved ejection fraction. Spironolactone did not significantly reduce the composite primary end point of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for heart failure.
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